Cardiology Pharmacy Specialty Review Course - includes Workbook (No Recert Credit (Cert # L219177)

ACPE Numbers: Various – see listing below
Pre-Sale Date: 05/26/2021
Content Release Date: 06/23/2021
Expiration Date: 05/13/2022
Activity Type: Application-based
CE Credits: 24 (ACPE only)
Activity Fee: $425 (ASHP member); $625 (non-member)

Accreditation for Pharmacists

The American College of Clinical Pharmacy and American Society of Health-System Pharmacists are accredited by the Accreditation Council for Pharmacy Education as providers of continuing pharmacy education.

Target Audience

These activities are intended for pharmacists who are seeking to update their knowledge and skills commensurate with a board certification examination in the areas listed below.

Activity Overview

This online course provides a robust preparatory curriculum for the pharmacy professional preparing for the Board of Pharmacy Specialties (BPS) Cardiology Specialty Certification Examination. Designed based on the domains, tasks, and knowledge statements developed by the BPS for the certification examination, this course will help you prepare for the exam by identifying areas needed for in‐depth review of cardiology issues by:

  • Reviewing pertinent clinical topics and practice skills
  • Providing exam practice questions
  • Listing valuable references for further study

This course is NOT intended for those obtaining recertification credit. To earn recertification credit, please see courses here:

These activities are part of the ACCP and ASHP professional development program.

Review Course

This course consists of 16 activities (see table below) and provides up to 24 hours of continuing pharmacy education credit. The Review Course includes case-based presentations for application to real-life scenarios, a practice exam along with correct answers, and links to the reference sources, and domains, tasks, and knowledge statements. To help you further prepare, this package includes a compilation of practice questions in the same format and rigor to help you prepare for the BPS Specialty Examination.       

Learning Activity

ACPE Number



ACPE Expiration Date

Primary Prevention of Cardiovascular Disease
and Public Health







Blood Pressure Management of Adult Patients 



Stable Atherosclerotic Disease 









Drug-Induced Cardiovascular Disease and Drugs to Avoid in Cardiovascular Disease



Chronic Heart Failure 



Acute Decompensated Heart Failure 



Cardiac Transplantation and Mechanical Circulatory Support 



Acute Coronary Syndromes 



Cardiovascular Emergencies 



Pulmonary Arterial Hypertension 



Specialized Topics in Cardiovascular Disease 



Principles of Information Management and Education



Principles of Cardiology Pharmacy Practice Administration
























Learning Objectives

Primary Prevention of Cardiovascular Disease and Public Health
ACPE #: 0217-9999-21-133-H01-P

  • Identify the pharmacotherapeutic agents that reduce the risk of developing cardiovascular disease (CVD).
  • Develop a treatment plan that incorporates lifestyle modifications and evidence-based pharmacotherapy to reduce the risk of an index cardiac event for a given patient scenario.
  • Develop a tobacco cessation plan for a patient who requests assistance for a quit attempt.
  • Evaluate a patient scenario to determine CVD risk and recommend appropriate lipid therapy.
  • Determine appropriate patients to recommend initiation of aspirin therapy for the primary prevention of CVD.
  • Counsel a patient on appropriate complementary and alternative pharmacotherapeutic agents to optimize CVD risk reduction, including vitamin D and omega-3 fatty acids.

ACPE #: 0217-9999-21-134-H01-P

  • Describe the role of cholesterol and lipoproteins in the development of atherosclerotic cardiovascular disease (ASCVD).
  • Evaluate a patient’s ASCVD risk by appropriately using the 10-year ASCVD Risk Pooled Cohort Equations and optional risk markers.
  • Establish goals of therapy, statin intensity and create a monitoring plan for patients receiving lipid-lowering therapies.
  • Develop an appropriate treatment regimen for patients who are statin intolerant or unable to achieve goals of therapy on maximally tolerated statin therapy, according to the 2018 Guideline on the Management of Blood Cholesterol.
  • Identify appropriate indications for the use of triglyceride-lowering therapies to manage hypertriglyceridemia.
  • Evaluate the needs of special populations (e.g., those with diabetes, older adults, those with kidney disease), and adapt treatment rategies to optimize outcomes.

Blood Pressure Management in Adult Patients
ACPE #: 0217-9999-21-135-H01-P

  • Develop an optimal pharmacologic treatment plan for a patient with hypertension (HTN) according to practice guidelines and clinical trial evidence.
  • Demonstrate appropriate drug selection and blood pressure goals for the treatment of HTN according to concomitant conditions and compelling indications.
  • Devise an evidence-based treatment strategy for resistant HTN to achieve blood pressure goals.
  • Construct appropriate drug therapy plans for the treatment of hypotension and/or antihypertensive drug related adverse events.

Stable Atherosclerotic Disease
ACPE #: 0217-9999-21-136-H01-P

  • Recommend patient-specific pharmacologic therapy for the management of stable ischemic heart disease (SIHD).
  • Differentiate between the antianginal options for a patient with refractory angina.
  • Develop an optimal pharmacologic regimen and monitoring plan for patients with peripheral arterial disease (PAD) considering individual patient symptomatology and characteristics.
  • Develop an evidence-based pharmacologic regimen for secondary prevention of ischemic stroke and transient ischemic attack (TIA).
  • Recommend risk factor modification strategies to prevent a recurrent event for patients with SIHD, PAD, and ischemic stroke/TIA.

ACPE #: 0217-9999-21-137-H01-P

  • Recommend a patient-specific pharmacotherapy plan to reduce the risk of stroke in patients with nonvalvular atrial fibrillation (NVAF).
  • Devise an evidence-based pharmacotherapy plan for preventing and treating venous thromboembolism (VTE).
  • Analyze the need for anticoagulant therapy in patients with atrial fibrillation or VTE.
  • Determine appropriate reversal strategies for patients at risk of active bleeding, or actively bleeding while receiving anticoagulation therapy.
  • Determine appropriate selection and dosing of anticoagulant therapy on the basis of patient-specific factors and drug interactions.
  • Evaluate literature and clinical implications of data for patients receiving anticoagulant agents.

ACPE #: 0217-9999-21-138-H01-P

  • Describe the principles of basic electrocardiogram (ECG) interpretation.
  • Compare and contrast risk factors for and etiologies, clinical features, signs and symptoms, and goals of therapy of sinus bradycardia, atrial fibrillation (AF), supraventricular tachycardia (SVT) (including Wolff-Parkinson-White [WPW] syndrome), premature ventricular complexes (PVCs), and ventricular tachycardia (VT).
  • Compare and contrast appropriate pharmacologic and nonpharmacologic treatment options for sinus bradycardia, AF, SVT, PVCs, and VT.
  • Compare and contrast the mechanisms of action of drugs used for ventricular rate control and conversion to and maintenance of sinus rhythm in patients with AF.
  • Describe the risk of thromboembolism in patients with AF and the importance of anticoagulation in this population.
  • Compare and contrast nonpharmacologic and pharmacologic methods of terminating and preventing recurrence of SVT
  • Compare and contrast nonpharmacologic and pharmacologic methods of terminating VT, preventing recurrence, and reducing the risk of sudden cardiac death
  • Develop evidence-based patient-specific pharmacotherapy plans for patients with symptomatic sinus bradycardia, AF, SVT (including WPW), PVCs, and VT.
  • Describe common and important drug-drug interactions associated with drugs used for the management of arrhythmias and their complications.

Drug-Induced Cardiovascular Disease and Drugs to Avoid in Cardiovascular Disease
ACPE #: 0217-9999-21-139-H01-P

  • Identify potential drug-induced cardiovascular diseases.
  • Analyze a medication list to determine causative agents for common drug-induced cardiovascular diseases.
  • Evaluate potential medications that can contribute to the development of torsades de pointes.
  • Review anticancer therapies that cause cardiovascular toxicities.
  • Evaluate patient characteristics and laboratory values to assess the risk of heparin- induced thrombocytopenia and develop an appropriate treatment plan.

Chronic Heart Failure
ACPE #: 0217-9999-21-140-H01-P

  • Given a patient with heart failure (HF), describe the classifications, staging, clinical presentation, etiologies, and diagnostic considerations.
  • Describe the pathophysiology of HF, focusing on the role that neurohormonal and other vasoactive agents play in HF progression.
  • Given a patient with chronic HF, devise an appropriate pharmacologic and nonpharmacologic therapeutic plan, with an emphasis on guideline-directed therapy and management.
  • Given a patient with chronic HF and several comorbidities, devise an appropriate evidence-based pharmacotherapy plan addressing specific comorbidities related to HF.

Acute Decompensated Heart Failure
ACPE #: 0217-9999-21-141-H01-P

  • Classify a patient with acute decompensated heart failure (ADHF) into a hemodynamic subset based on signs/symptoms, laboratory values, and hemodynamic measures obtained via pulmonary artery catheter (PAC) monitoring.
  • Design an initial pharmacotherapeutic treatment and monitoring plan for a patient with ADHF based on hemodynamic subset.
  • Devise a modified treatment and monitoring plan in a patient with ADHF and diuretic resistance.
  • Compare and contrast the use of intravenous (IV) vasodilators and positive inotropes in the treatment of ADHF, and among the agents within each drug class.
  • List strategies for reducing the risk of heart failure (HF) readmission among patients recovering from ADHF.

Cardiac Transplantation and Mechanical Circulatory Support
ACPE #: 0217-9999-21-142-H01-P

  • Evaluate levels of risk in the cardiac transplant candidate.
  • Derive rational peri- and postoperative rejection mitigation strategies in cardiac transplant recipients.
  • Devise effective thromboprophylactic strategies for patients receiving percutaneous ventricular assist device support.
  • Construct safe and effective drug therapy regimens for patients receiving extracorporeal membrane oxygenation support
  • Design effective treatment plans for patients with complications of durable left ventricular support device therapy.

Acute Coronary Syndromes
ACPE #: 0217-9999-21-143-H01-P

  • Distinguish between reperfusion strategies for acute coronary syndrome (ACS): ST- segment elevation myocardial infarction (STEMI) and non–ST-segment elevation (NSTE) ACS.
  • Devise a pharmacotherapeutic treatment plan for a patient with STEMI undergoing primary percutaneous coronary intervention (PCI) and for a patient with NSTE-ACS undergoing an early invasive or ischemic-guided approach.
  • Differentiate between the best possible pharmacologic options for preventing thrombotic events in the acute management of ACS.
  • Analyze differences in evidence, pharmacology, pharmacokinetics, drug-drug interactions, monitoring, and adverse events between the P2Y12 inhibitors and anticoagulants used in ACS management.
  • Devise an individualized evidence-based treatment plan for patients in need of secondary prevention post-ACS, including mortality-reducing therapies.

Cardiovascular Emergencies
ACPE #: 0217-9999-21-144-H01-P

  • Choose appropriate management pathways/treatment for a patient with cardiac arrest according to patient presentation.
  • Differentiate between the various categories of shock.
  • Select the optimal management strategies for the various types of shock.
  • Construct a pharmacotherapy regimen for the various hypertensive crises.
  • Select an appropriate management plan for a patient presenting with acute aortic syndrome.
  • Design a pharmacotherapy plan for the management of acute ischemic stroke.

Pulmonary Arterial Hypertension
ACPE #: 0217-9999-21-145-H01-P

  • Describe the classification of pulmonary hypertension and implications for treatment.
  • Discuss the importance of pulmonary arterial hypertension (PAH) pathobiology and the role of various pathways as treatment targets in the development of PAH-specific treatment.
  • Define treatment goals for the management of PAH.
  • Outline targeted medications for PAH, including indications, dosing, monitoring, and their place within current treatment algorithms.
  • Identify common adverse effects and drug interactions associated with PAH medications.
  • Highlight appropriate treatment approaches for the management of decompensated PAH.
  • Design a treatment plan for a patient with PAH.

Specialized Topics in Cardiovascular Disease
ACPE #: 0217-9999-21-146-H01-P

  • Recommend empiric antibiotic therapy for patients with suspected infective endocarditis (IE).
  • Develop a therapeutic plan regarding medication therapy for patients with IE or patients requiring prophylactic therapy for IE prevention.
  • Identify patients who require IE prophylactic therapy.
  • Develop a treatment plan for patients with pericarditis.
  • Recommend appropriate therapy for patients with myocarditis.
  • Plan a medication therapy regimen for patients with valvular heart disease.

Principles of Information Management and Education
ACPE #: 0217-9999-21-147-H04-P

  • Identify different types of data (nominal, ordinal, continuous) to determine the appropriate type of statistical test (parametric vs. nonparametric).
  • Select appropriate statistical tests based on the sample distribution, data type, and study design.
  • Identify the most appropriate study design to answer a given clinical question.
  • Describe the key tenets of internal and external validity of cardiovascular-related trials.
  • Describe the advantages and disadvantages of surrogate and composite outcomes in cardiovascular studies.

Principles of Cardiology Pharmacy Practice Administration
ACPE #: 0217-9999-21-148-H04-P

  • Develop policies, procedures, and clinical protocols related to the medication use process.
  • Identify formulary management activities to improve the prescribing of safe, effective, and affordable treatments in an organization.
  • List high-risk medications and medication-related processes that are suited for a medication use evaluation (MUE) and be capable of managing the MUE process.
  • Identify sources of quality measures relevant to your organization, and use quality and process improvement methods to achieve optimal outcomes.
  • Describe proper documentation practices for clinical pharmacy services and identify the need for accurate documentation.
  • Review pharmacoeconomic principles and their application to patient care.
  • Define a pharmacist’s scope of practice and the importance of credentialing and privileging.
  • Compare a medication error, adverse drug event (ADE), adverse drug reaction (ADR), and preventable ADE.
  • Design an ADE reporting program, including committee structure, committee reporting mechanisms, and methods of detecting, reporting, and managing ADEs.


Full faculty bios

William L. Baker, Pharm.D., FCCP, FACC, FAHA
Associate Professor, Department of Pharmacy Practice
University of Connecticut School of Pharmacy
Storrs, Connecticut

Theodore Berei, Pharm.D., MBA, BCPS, BCCP
Clinical Specialist Advanced Heart Failure
University of Wisconsin Health
Madison, Wisconsin

Scott Bolesta, Pharm.D., FCCP, FCCM, BCPS
Associate Professor, Department of Pharmacy Practice
Nesbit School of Pharmacy, Wilkes University
Wilkes-Barre, Pennsylvania

Jonathan D. Cicci, Pharm.D., BCPS, BCCP, CPP
Clinical Pharmacy Specialist, Cardiology Clinical Pharmacist Practitioner, Cardiology
University of North Carolina Medical Center
Clinical Assistant Professor
UNC Eshelman School of Pharmacy
Chapel Hill, North Carolina

James C. Coons, Pharm.D., FCCP, BCCP
Associate Professor
University of Pittsburgh School of Pharmacy
Clinical Pharmacist, Cardiology
UPMC Presbyterian Hospital
PGY2 Cardiology Residency Program Director
Pittsburgh, Pennsylvania

Paul P. Dobesh, Pharm.D., FCCP, BCPS, BCCP
Professor of Pharmacy Practice
University of Nebraska Medical Center
College of Pharmacy
Omaha, Nebraska

Steve Dunn, Pharm.D., FCCP, FAHA, BCPS, BCCP
Pharmacy Clinical Coordinator, Heart and Vascular
University of Virginia Health System
Charlottesville, Virginia

Shannon Finks, Pharm.D., FCCP, FACC, BCPS, BCCP, AHSCP-CHC
Professor, Department of Clinical Pharmacy
University of Tennessee
College of Pharmacy
Memphis, Tennessee

Genevieve Hale, Pharm.D., BCPS, BCCP, CPh
Palm Beach Gardens Campus Vice Chair
Assistant Professor, Department of Pharmacy Practice
Nova Southeastern University
College of Pharmacy
Palm Beach Gardens, Florida

Doug Jennings, Pharm.D., FCCP, FAHA, FACC, FHFSA, BCPS
Clinical Pharmacy Manager, Heart Transplant
New York Presbyterian Hospital
Columbia University Irving Medical Center
New York, New York

Tracy E. Macaulay, Pharm.D., BCPS-AQ Cardiology, BCCP, AACC
Associate Professor, University of Kentucky College of Pharmacy
Cardiology Clinical Pharmacy Specialist
UK HealthCare
Lexington, Kentucky

Zachary Noel, Pharm.D., BCPS, BCCP
Assistant Professor, Department of Pharmacy Practice and Science
University of Maryland School of Pharmacy
Baltimore, Maryland

Brent Reed, Pharm.D., BCPS, BCCP
Associate Professor of Pharmacy Practice and Science
University of Maryland School of Pharmacy
Baltimore, Maryland

Kelly C. Rogers, Pharm.D., FCCP, FACC, BCCP
Professor, Department of Clinical Pharmacy and Translational Science
University of Tennessee College of Pharmacy
Memphis, Tennessee

Dustin Spencer, Pharm.D., MBA, BCPS, BCCP
Clinical Director, Cardiopulmonary Diseases
Cardinal Health
Houston, Texas

Nathan J. Verlinden, Pharm.D., BCPS, BCCP
Cardiology Clinical Pharmacy Specialist
Allegheny General Hospital
Pittsburgh, Pennsylvania

*Content matter experts


Brandon Cave, Pharm.D., BCCP, ASH-CHC
Mary Blanton Covell, Pharm.D., MPH, BCPS, BCCP
Anne Denham, Pharm.D., BCPS-AQ Cardiology
Sandeep Devabhakthuni, Pharm.D., BCCP
Cynthia Jackevicius, Pharm.D., M.Sc., FCCP, FAHA, FCCS, BCCP, BCPS-AQ Cardiology
Michael S. Kelly, Pharm.D., FNLA, BCACP, CLS
Kazuhiko Kido, Pharm.D., M.S., BCPS, BCCP
Kristin Montarella, Pharm.D., BCPS, BCPP
Kari L. Olson, Pharm.D., FCCP, BCPS
Brent Reed, Pharm.D., BCPS, BCCP
Andrew J. Smith, Pharm.D., FCCP, BCCP, BCPS
Elisabeth M. Sulaica, Pharm.D., BCCP
Jerrica E. Waggoner, PharmD, BCPS, BCCP
Barbara S. Wiggins, Pharm.D., FCCP, FAHA, FNLA, FACC, BCPS, BCCP, BCCCP, CLS
Kevin Wohlfarth, Pharm.D., BCPS, BCCCP, BCCP


In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support and the Accreditation Council for Pharmacy Education’s Standards for Commercial Support, ASHP requires that all individuals involved in the development of activity content disclose their relevant financial relationships. A person has a relevant financial relationship if the individual of his or her spouse/partner has a financial relationship (e.g. employee, consultant, research grant recipient, speakers bureau, or stockholder) in any amount occurring the in the last 12 months with a commercial interest whose products or series may be discussed in the educational activity content over which the individual has control. The existence of these relationships is provided for the information of participants and should not be assumed to have an adverse impact on the content. 

All faculty and planners for ASHP education activities are qualified and selected by ASHP and required to disclose any relevant financial relationships with commercial interests. ASHP identifies and resolves conflicts of interest prior to an individual’s participation in development of content for an educational activity. Anyone who refuses to disclose relevant financial relationships must be disqualified from any involvement with a continuing pharmacy education activity. 

Faculty Disclosures:

  • Received Grant Funding/Research Support: William L. Baker (Alexion), James C. Coons (United Therapeutics)
  • Consultant/Member of Advisory Board: William L. Baker (Bayer AG), James C. Coons (Alnylam Pharmaceuticals, Bristol-Myers Squibb, Portola), Paul P. Dobesh (BMS-Pfizer Alliance, Janssen), Steve Dunn (Abiomed)

Reviewer Disclosures:

  • Speaker’s Bureau: Brandon Cave (Alexion), Jerrica E. Waggoner (Janssen) 

All other planners, presenters, reviewers, ACCP and ASHP staff, and others with an opportunity to control content report no financial relationships relevant to this activity. 

Methods and CE Requirements

Activities can be completed in any order. Each activity consists of audio, video, and/or PDFs and evaluations. Learners must review all content and complete the evaluations to receive continuing pharmacy education credit for each activity. 

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity. 

System Technical Requirements

Courses and learning activities are delivered via your Web browser and Acrobat PDF. For all activities, you should have a basic comfort level using a computer and navigating web sites. 

View the minimum technical and system requirements for learning activities. 


These activities were developed by ACCP and ASHP.

To maintain its strict, independent standards for certification, BPS does NOT endorse or provide review information, preparatory courses, or study guides for Board Certification Examinations.